uric acid has been researched along with Infections, Respiratory in 5 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and safety of febuxostat extended release (XR) and immediate release (IR) in patients with gout and normal or impaired renal function." | 9.30 | Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. ( Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019) |
| "Using mass spectrometry, oxidation products of glutathione and uric acid were measured in matched samples of bronchoalveolar lavage (BAL), serum and urine from 36 infants and children with CF, and related to markers of neutrophilic inflammation and infection in BAL." | 7.85 | Oxidized glutathione and uric acid as biomarkers of early cystic fibrosis lung disease. ( Dickerhof, N; Fantino, E; Kettle, AJ; Khalilova, I; Sly, PD; Turner, R, 2017) |
| "To assess the efficacy and safety of febuxostat extended release (XR) and immediate release (IR) in patients with gout and normal or impaired renal function." | 5.30 | Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. ( Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019) |
| "Using mass spectrometry, oxidation products of glutathione and uric acid were measured in matched samples of bronchoalveolar lavage (BAL), serum and urine from 36 infants and children with CF, and related to markers of neutrophilic inflammation and infection in BAL." | 3.85 | Oxidized glutathione and uric acid as biomarkers of early cystic fibrosis lung disease. ( Dickerhof, N; Fantino, E; Kettle, AJ; Khalilova, I; Sly, PD; Turner, R, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saag, KG | 1 |
| Becker, MA | 1 |
| Whelton, A | 1 |
| Hunt, B | 1 |
| Castillo, M | 1 |
| Kisfalvi, K | 1 |
| Gunawardhana, L | 1 |
| Dickerhof, N | 1 |
| Turner, R | 1 |
| Khalilova, I | 1 |
| Fantino, E | 1 |
| Sly, PD | 1 |
| Kettle, AJ | 1 |
| Kundu, AK | 1 |
| Nessan, VJ | 1 |
| Geerken, RC | 1 |
| Ulvilla, J | 1 |
| Pokorný, M | 1 |
| Resl, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout[NCT02139046] | Phase 3 | 1,790 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A participant was considered to have a gout flare if the following criteria were met:~Participant-reported acute particular pain typical of a gout attack that was deemed by participant and/or investigator to require treatment and was treated with colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids, Participant experienced at least 3 or more of: 1) Joint swelling, 2) Redness, 3) Tenderness, 4) Pain, Participant experienced at least one or more of: 1) Rapid onset of pain, 2) Decreased range of motion, 3) Joint warmth, 4) Other symptoms similar to a prior gout flare." (NCT02139046)
Timeframe: Baseline to Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 20.7 |
| Febuxostat IR 40 mg | 21.0 |
| Febuxostat XR 40 mg | 22.8 |
| Febuxostat IR 80 mg | 27.2 |
| Febuxostat XR 80 mg | 26.6 |
(NCT02139046)
Timeframe: Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.3 |
| Febuxostat IR 40 mg | 15.7 |
| Febuxostat XR 40 mg | 25.9 |
| Febuxostat IR 80 mg | 42.6 |
| Febuxostat XR 80 mg | 50.1 |
(NCT02139046)
Timeframe: Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.6 |
| Febuxostat IR 40 mg | 40.3 |
| Febuxostat XR 40 mg | 48.2 |
| Febuxostat IR 80 mg | 57.7 |
| Febuxostat XR 80 mg | 61.1 |
1 trial available for uric acid and Infections, Respiratory
| Article | Year |
|---|---|
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Colchicine; Cough; Creatinine; Delay | 2019 |
4 other studies available for uric acid and Infections, Respiratory
| Article | Year |
|---|---|
Oxidized glutathione and uric acid as biomarkers of early cystic fibrosis lung disease.
Topics: Biomarkers; Bronchoalveolar Lavage Fluid; Child, Preschool; Cystic Fibrosis; Early Diagnosis; Female | 2017 |
Acute gout in a patient taking pefloxacin--a case report.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Gout; Humans; Male; Pefloxacin; Respiratory Tract In | 1996 |
Uric acid excretion in infectious mononucleosis: a function of increased purine turnover.
Topics: Creatinine; Humans; Infectious Mononucleosis; Purines; Respiratory Tract Infections; Uric Acid | 1974 |
Psoriasis and factors affecting the level of uricaemia.
Topics: Female; Follow-Up Studies; Gout; Humans; Male; Obesity; Psoriasis; Respiratory Tract Infections; Sex | 1968 |